The INFUSE study aims to assess the real-world effectiveness of eptinezumab for preventive treatment of migraine in patients in whom ≥1 preventive calcitonin gene-related peptide antagonist (anti-CGRP) had previously failed.

The efficacy and safety of eptinezumab, an anti-CGRP monoclonal antibody administered intravenously for the preventive treatment of migraine in adults, have been demonstrated in multiple clinical trials.

The INFUSE study is an ongoing observational, prospective study with patients potentially recruited from ≥100 US infusion centers. This study includes adults with a migraine diagnosis in whom ≥1 preventive anti-CGRP (subcutaneous monoclonal antibodies and preventive oral gepants) had failed due to a lack of effectiveness or side effects and who were initiating eptinezumab treatment. Data are remotely collected on a web-based platform. The current interim analysis evaluated patient-reported outcomes through Month 6 (after 2 eptinezumab infusions), including Patient Global Impression of Change (PGIC); monthly headache days (MHDs) and 50% reduction in MHDs, both from the Migraine Disability Assessment (MIDAS); and patient-defined “good days.”

In the overall interim analysis population (female, 89% [67/75]; mean±SD age, 46.0±14.5 years), 60% (45/75) of patients reported that ≥3 anti-CGRPs had failed, with high disease burden recorded across measures at baseline. In the interim effectiveness analysis population (N=48) after 6 months of eptinezumab treatment, 71% (95% CI: 57%-82%) of patients reported any improvement (minimally, much, or very much improved). The mean MHD reduction was 5.8 days/month (P<0.001; baseline: 19.0 MHDs) on MIDAS; a MIDAS-derived ≥50% reduction in MHDs was achieved by 42% (95% CI: 29%-56%) of patients; and an increase of 5.3 good days/month was reported (P<0.001; baseline: 10.0 days/month). Results for the full study population at 6 months will be reported in the presented poster.

Improvements across multiple migraine outcomes were reported after switch to eptinezumab in patients for whom prior anti-CGRP therapies have failed.